CLAIMS

1. Use of an anti-OSMRß antibody in the manufacture of a medicament for the treatment of prurigo nodularis (PN), wherein the medicament is to be administered to a subject in need of treatment at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of prurigo nodularis relative to a control, wherein the therapeutically effective dose is

(a) a flat dose, wherein the flat dose is equal to or greater than 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 320 mg, 360 mg, 380 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 720 mg, 740 mg, 760 mg, 780 mg or 800 mg; or

(b) equal to or greater than 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 7.5 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg or 20 mg/kg, 50 mg/kg, 100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mg/kg, 550 mg/kg, 600 mg/kg, 650 mg/kg, 700 mg/kg, 750 mg/kg, 800 mg/kg, 850 mg/kg, 900 mg/kg, 950 mg/kg, or 1000 mg/kg;

and wherein the anti-OSMRß antibody comprises:

a light chain complementary-determining region 1 (LCDR1) defined by SEQ ID NO: 8, a light chain complementary-determining region 2 (LCDR2) defined by SEQ ID NO: 9, and a light chain complementary-determining region 3 (LCDR3) defined by SEQ ID NO: 10; and

a heavy chain complementary-determining region 1 (HCDR1) defined by SEQ ID NO: 5, a heavy chain complementary-determining region 2 (HCDR2) defined by SEQ ID NO: 6, and a heavy chain complementary-determining region 3 (HCDR3) defined by SEQ ID NO: 7.

2. The use of claim 1, wherein the subject presents with pruritic hyperkeratotic nodules.

3. The use of claim 1, wherein the prurigo nodularis is idiopathic.

4. The use of any one of claims 1-3, wherein the prurigo nodularis is not associated with any other underlying co-morbidities.

5. The use of claim 1 or 2, wherein the prurigo nodularis is associated with one or more underlying co-morbidities.

6. The use of any one of the preceding claims, wherein IL-31, IL-31Rα, OSM and/or OSMRβ expression level is elevated in the subject relative to a control, optionally wherein the ~~levels~~ level of any one of IL-31, IL-31Rα, OSM and OSMRβ in the subject is determined via skin biopsy from hyperkeratotic nodules, further optionally wherein the control is a healthy subject, who is not diagnosed with a pruritic disease.

7. The use of any one of the preceding claims, wherein the subject in need of treatment has a score on a pruritus Numerical Rating Score (NRS) greater than or equal to 5, or greater than or equal to 7.

8. The use of any one of the preceding claims, wherein the subject in need of treatment has elevated MCP-1/CCL2 levels in comparison to a control subject, optionally wherein treating results in a reduction of MCP-1/CCL2 levels in the subject, optionally wherein treating results in a reduction of MCP-1/CCL2 levels in the subject, optionally to levels equivalent to levels in a healthy subject.

9. The use of any one of preceding claims, wherein the medicament is to be administered subcutaneously.

10. The use of any one of claims 1-8, wherein the medicament is to be administered intravenously.

~~11. The use of any one of the preceding claims, wherein the therapeutically effective dose is equal to or greater than 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 7.5 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg or 20 mg/kg, or wherein the therapeutic effective dose is equal to or greater than 50 mg/kg, 100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mg/kg, 550 mg/kg, 600 mg/kg, 650 mg/kg, 700 mg/kg, 750 mg/kg, 800 mg/kg, 850 mg/kg, 900 mg/kg, 950 mg/kg, or 1000 mg/kg.~~

~~12. The use of any one of the preceding claims, wherein the therapeutically effective dose is a flat dose, wherein the flat dose is equal to or greater than 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 320 mg, 360 mg, 380 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 720 mg, 740 mg, 760 mg, 780 mg or 800 mg.~~

~~13.~~11. The use of any one of the preceding claims, ~~wherein the anti-OSMRß antibody comprises:~~

~~a light chain complementary-determining region 1 (LCDR1) defined by SEQ ID NO: 8, a light chain complementary-determining region 2 (LCDR2) defined by SEQ ID NO: 9, and a light chain complementary-determining region 3 (LCDR3) defined by SEQ ID NO: 10; and~~

~~a heavy chain complementary-determining region 1 (HCDR1) defined by SEQ ID NO: 5, a heavy chain complementary-determining region 2 (HCDR2) defined by SEQ ID NO: 6, and a heavy chain complementary-determining region 3 (HCDR3) defined by SEQ ID NO: 7;~~

~~optionally~~ wherein the anti-OSMRß antibody comprises:

a light chain variable domain having an amino acid sequence at least 90% identical to SEQ ID NO: 4; and

a heavy chain variable domain having an amino acid sequence at least 90% identical to SEQ ID NO: 3;

further optionally wherein

the light chain variable domain has the amino acid sequence set forth in SEQ ID NO: 4; and

the heavy chain variable domain has the amino acid sequence set forth in SEQ ID NO: 3.

~~14.~~12. The use of claim 11~~claim 13~~, wherein the anti-OSMRß antibody comprises CH1, hinge and CH2 domains derived from an IgG4 antibody fused to a CH3 domain derived from an IgG1 antibody,

optionally wherein the anti-OSMRß antibody comprises

a light chain having an amino acid sequence at least 90% identical to SEQ ID NO: 2; and

a heavy chain having an amino acid sequence at least 90% identical to SEQ ID NO: 1,

further optionally wherein

the light chain has the amino acid sequence set forth in SEQ ID NO: 2; and

the heavy chain has the amino acid sequence set forth in SEQ ID NO: 1.

~~15.~~ 13. The use of any one of the preceding claims, wherein the medicament to be administered results in a decrease in pruritus Numerical Rating Score (NRS) compared to a control, optionally wherein the control is a NRS indicative of a subject with comparable disease status without treatment, or a NRS in the subject prior to the treatment.